A phase I trial testing a new generation FLT-3 inhibitor quizartinib showed promising outcomes in children with MLL-r ALL or refractory AML [90], although concerns on resistance in AML have been reported [91]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.